EICHOR
● Active Not Recruiting
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
Condition: Hypertriglyceridemia · Sponsor: Arrowhead Pharmaceuticals
About this study
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (235)
| Research Site 1 | Birmingham, Alabama, United States | — |
| Research Site 2 | Mobile, Alabama, United States | — |
| Research Site 3 | Beverly Hills, California, United States | — |
| Research Site 4 | Canoga Park, California, United States | — |
| Research Site 5 | Garden Grove, California, United States | — |
| Research Site 6 | Huntington Beach, California, United States | — |
| Research Site 7 | Lake Forest, California, United States | — |
| Research Site 8 | Lincoln, California, United States | — |
| Research Site 9 | Long Beach, California, United States | — |
| Research Site 10 | Montclair, California, United States | — |
| Research Site 11 | Oxnard, California, United States | — |
| Research Site 12 | Redding, California, United States | — |
+ 223 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.